1. Home
  2. BVFL vs SPRO Comparison

BVFL vs SPRO Comparison

Compare BVFL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BV Financial Inc.

BVFL

BV Financial Inc.

HOLD

Current Price

$19.35

Market Cap

168.6M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.45

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
SPRO
Founded
1873
2013
Country
United States
United States
Employees
N/A
25
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
135.5M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
BVFL
SPRO
Price
$19.35
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.8K
277.5K
Earning Date
04-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
111.81
EPS
1.43
0.15
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.38
$15.60
Revenue Growth
N/A
39.24
52 Week Low
$13.53
$0.51
52 Week High
$19.88
$3.09

Technical Indicators

Market Signals
Indicator
BVFL
SPRO
Relative Strength Index (RSI) 52.15 54.43
Support Level $18.22 $2.15
Resistance Level $19.81 $2.70
Average True Range (ATR) 0.46 0.13
MACD 0.04 -0.01
Stochastic Oscillator 74.64 46.94

Price Performance

Historical Comparison
BVFL
SPRO

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: